4
Changes in Ownership
Arcutis Biotherapeutics, Inc. Filed Acc 0001628280-26-014325
SVP Chief Financial Officer sold 2,853 shares at an average $25.18 ($71,844)
- SVP Chief Financial Officer acquired 27,000 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Vairavan Latha · SVP Chief Financial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-27 | Grant or award : show line 1 in the form 10b5-1 | +27,000 | 90,607 | D | ||
| 2026-03-02 | Sale : show line 2 in the form 10b5-1 | −2,772 | $25.16 | $69,745 | 87,835 | D |
| 2026-03-02 | Sale : show line 3 in the form 10b5-1 | −81 | $25.91 | $2,099 | 87,754 | D |
| Open-market sales · 2,853 sh · avg $25.18 · $71,844 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-27 | Grant or award : show line 4 in the form 10b5-1 Stock Option (right to buy) | +70,000 | 70,000 | D |
Loading xslF345X05/wk-form4_1772588527.xml…